A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

Abstract Introduction The purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [14C]-AG-221. Methods This was a phase 1, open-label study. Si...

Full description

Bibliographic Details
Main Authors: Xiaomin Wang, Jian Chen, Josephine Reyes, Simon Zhou, Maria Palmisano, Yan Li
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-07-01
Series:Oncology and Therapy
Subjects:
Absolute bioavailability
Accelerator mass spectrometry
AG-221
Relapsed or refractory acute myeloid leukemia
Online Access:http://link.springer.com/article/10.1007/s40487-019-0097-7

Internet

http://link.springer.com/article/10.1007/s40487-019-0097-7

Similar Items